Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXFP1 | Q9HBX9 | 2/20 | 0.48 |
| ▸ | AURKA | O14965 | 2/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.43 |
| ▸ | MAPT | P10636 | 3/20 | 0.43 |
| ▸ | POLB | P06746 | 2/20 | 0.43 |
| ▸ | P2RY1 | P47900 | 1/20 | 0.42 |
| ▸ | KDR | P35968 | 2/20 | 0.41 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.41 |
| ▸ | IDH1 | O75874 | 1/20 | 0.41 |
| ▸ | VNN1 | O95497 | 1/20 | 0.41 |
| ▸ | SAE1 | Q9UBE0 | 1/20 | 0.40 |
| ▸ | UBA2 | Q9UBT2 | 1/20 | 0.40 |
| ▸ | ELANE | P08246 | 2/20 | 0.40 |
| ▸ | AHSA1 | O95433 | 1/20 | 0.40 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19639775 | 0.83 | RXFP1 (0.47) | RXFP1AURKAKDM4EMAPTP2RY1 | |
| SCHEMBL19639813 | 0.82 | AURKA (0.42) | RXFP1AURKAKDM4EMAPTPOLB | |
| SCHEMBL19640095 | 0.80 | ELANE (0.49) | RXFP1AURKAKDM4EMAPTP2RY1 | |
| SCHEMBL19684716 | 0.78 | MAPT (0.43) | RXFP1AURKAKDM4EMAPTPOLB | |
| SCHEMBL19639785 | 0.77 | ELANE (0.41) | RXFP1AURKAKDM4EMAPTPOLB | |
| SCHEMBL19639815 | 0.77 | RORC (0.41) | RXFP1AURKAKDM4EMAPTPOLB | |
| SCHEMBL19639795 | 0.76 | ELANE (0.39) | RXFP1AURKAKDM4EMAPTPOLB | |
| SCHEMBL19684540 | 0.74 | PDE4B (0.37) | VNN1 | |
| SCHEMBL19651232 | 0.70 | NR4A1 (0.42) | — | |
| SCHEMBL19639779 | 0.69 | ELANE (0.45) | ELANE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3464269-B1 | HETEROCYCLIC COMPOUNDS FOR USE IN THE TREATMENT OF A HNE RELATED DISEASE | CHIESI FARM SPA (IT) | 2020-04-01 | — | — | EP | disclosed |
| EP-3464268-B1 | NOVEL COMPOUNDS | CHIESI FARM SPA (IT) | 2020-03-11 | — | — | EP | disclosed |
| EP-3464268-A1 | NOVEL COMPOUNDS | Chiesi Farmaceutici S.p.A. (IT) | 2019-04-10 | — | — | EP | disclosed |
| US-10172830-B2 | Pyrazolone compounds having human neutrophil elastase inhibitory properties | CHIESI FARMACEUTICI S.P.A. (IT) | 2019-01-08 | — | — | US | disclosed |
| US-10172830-B2 | Pyrazolone compounds having human neutrophil elastase inhibitory properties | CHIESI FARMACEUTICI S.P.A. (IT) | 2019-01-08 | — | — | US | disclosed |
| WO-2017207433-A9 | HETEROCYCLIC COMPOUNDS FOR USE IN THE TREATMENT OF A DISEASE IN WHICH HNE IS IMPLICATED | CHIESI FARMACEUTICI S.P.A. (IT) | 2018-03-01 | — | — | WO | disclosed |
| US-9862706-B2 | Compounds | CHIESI FARMACEUTICI S.P.A. (IT) | 2018-01-09 | — | — | US | disclosed |
| WO-2017207433-A1 | HETETOCYCLIC COMPOUNDS FOR USE IN THE TREATMENT OF A DISEASE IN WHICH HNE IS IMPLICATED | CHIESI FARMACEUTICI S.P.A. (IT) | 2017-12-07 | — | — | WO | disclosed |
| WO-2017207432-A1 | NOVEL COMPOUNDS | CHIESI FARMACEUTICI S.P.A. (IT) | 2017-12-07 | — | — | WO | disclosed |
| WO-2017207432-A1 | NOVEL COMPOUNDS | CHIESI FARMACEUTICI S.P.A. (IT) | 2017-12-07 | — | — | WO | disclosed |
| US-20170342056-A1 | NOVEL COMPOUNDS | CHIESI FARMACEUTICI S.P.A. (IT) | 2017-11-30 | — | — | US | disclosed |
| US-20170340611-A1 | NOVEL COMPOUNDS | CHIESI FARMACEUTICI S.P.A. (IT) | 2017-11-30 | — | — | US | disclosed |
| US-20170342056-A1 | NOVEL COMPOUNDS | CHIESI FARMACEUTICI S.P.A. (IT) | 2017-11-30 | — | — | US | disclosed |
| US-20170340611-A1 | NOVEL COMPOUNDS | CHIESI FARMACEUTICI S.P.A. (IT) | 2017-11-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170340611-A1 | NOVEL COMPOUNDS | SERPINB1, ELANE, MPO | RXFP1 4447/4885AURKA 4842/4885KDM4E 4400/4885 |
| US-20170342056-A1 | NOVEL COMPOUNDS | SERPINB1, ELANE, MPO | RXFP1 4597/4885AURKA 4765/4885KDM4E 4520/4885 |
| US-10172830-B2 | Pyrazolone compounds having human neutrophil elastase inhibitory properties | SERPINB1, ELANE, EPX | RXFP1 4389/4885AURKA 4752/4885KDM4E 4206/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.